Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

Marie Skłodowska-Curie Action · Running

ISOBIOTICS Isotopic Labeling of Biotherapeutics

Coordinator
Commissariat a L Energie Atomique Et Aux Energies Alternatives, France
Runs
1 February 2023 to 31 January 2027
Status
Running
EU funding
€2.7m
Total cost
—
Partners
18 organisations in 7 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101072780

What the project is doing

In the project's own words, from its summary on CORDIS.

Biological drugs such as peptides, proteins, oligonucleotides and analogs provide the patients with more efficacious and less toxic treatments and have lower attrition rates than chemical drugs since 1 on 9 new biological entities entering clinical trials reaches the market (1 on 16 for chemical drugs). Consequently, 15 on 24 top blockbuster drugs were biotherapeutics in 2020 (world-market share of about 40% of $175 billion of revenue per year).

In order to reduce the immunogenicity of biodrugs, to overcome their fragility and to increase their capacity to reach quickly and massively their target, reduced-size biologics are extensively developed. However, radiolabeling of large molecules by grafting bifunctional chelating agents which do not alter significantly their biological activity is thus no longer possible with smaller biodrugs. It is therefore of paramount importance to devise new radiolabeling approaches carried out on tiny quantities in aqueous media and very soft conditions.

It is also crucial to train a new generation of radiochemists in order to implement these methods and to meet the needs of the European industry. ISOBIOTICS ambitions: 1) to develop new chemically-benign strategies for the last-stage radiolabeling of large peptides, small/medium-size proteins, oligonucleotides and analogs with deuterium, tritium and carbon-14 (preclinical and phase 0 clinical evaluation), and fluorine-18 (phase I-III clinical trials); 2) to educate a new generation of young talented PhD students specialized in the radiolabeling of biologics through a combination of interdisciplinary lab research, transdisciplinary and intersectorial secondments, technical taught courses, scientific lectures and complementary skills workshops; 3) to ensure the appropriate dissemination, exploitation and communication of all ISOBIOTICS outputs in order to maximize the project’s impact and radiance; 4) to secure the students employment and the sustainability of training structures.

Topics

Who is involved

OrganisationCityCountryRole
Commissariat a L Energie Atomique Et Aux Energies AlternativesParisFranceCoordinator
Leibniz Institut Fuer Katalyse eVRostockGermanyAssociatedpartner
Ludwig-Maximilians-Universitaet MuenchenPlaneggGermanyParticipant
Sanofi-Aventis Deutschland GmbHFrankfurt Am MainGermanyParticipant
Aarhus UniversitetAarhus CDenmarkAssociatedpartner
Agencia Estatal Consejo Superior De Investigaciones CientificasMadridSpainAssociatedpartner
Institut Quimic De SarriaBarcelonaSpainAssociatedpartner
Universite Paris-SaclayGif-Sur-YvetteFranceAssociatedpartner
Chemprecise Consultoria Biotecnologia Produtos Farmaceuticos E Imobiliario LdaTorres VedrasPortugalParticipant
Faculdade De Medicina Da Universidade De LisboaLisboaPortugalAssociatedpartner
Fundacao Gimm - Gulbenkian Institute for Molecular MedicineLisboaPortugalParticipant
Faculdade de Farmácia da Universidade de LisboaLisboaPortugalAssociatedpartner
Astrazeneca ABSodertaeljeSwedenParticipant
Karolinska InstitutetStockholmSwedenAssociatedpartner
Astrazeneca UK LimitedCambridgeUnited KingdomAssociatedpartner
The Chancellor Masters and Scholars of the University of CambridgeCambridgeUnited KingdomAssociatedpartner
The Chancellor, Masters and Scholars of the University of OxfordOxfordUnited KingdomAssociatedpartner
The Rosalind Franklin InstituteDidcotUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI